ABSTRACT
Platelet-type von Willebrand disease (PT-VWD) is an autosomal dominant rare bleeding disorder characterized by hyperresponsive platelets. This inherent platelet function defect is due to a gain-of-function mutation within the GP1BA gene coding for the platelet surface glycoprotein Ib alpha protein, the receptor for the adhesive protein von Willebrand factor (VWF). The defect results in excessive and unnecessary platelet–VWF interaction with subsequent removal of the hemostatically efficient high molecular weight VWF as well as platelets from the circulation, leading to thrombocytopenia and bleeding diathesis. Patients with PT-VWD present with mild to moderate mucocutaneous bleeding, which becomes more pronounced during pregnancy and following aspirin ingestion or drugs that have antiplatelet activity. Laboratory testing shows low VWF:ristocetin cofactor and low or normal VWF:antigen and characteristically an enhanced ristocetin-induced platelet agglutination (RIPA). These laboratory features are also indicators of the closely similar and more common bleeding disorder type 2B VWD. Simplified RIPA mixing assays, cryoprecipitate challenge, and flow cytometry can differentiate between the two disorders. However, the gold standard is to identify mutations within the VWF gene (indicating type 2B VWD) or the platelet GP1BA gene ( confirming PT-VWD). Treatment is based on making a correct diagnosis of PT-VWD where platelet concentrates instead of VWF/factor VIII preparations should be administered. A recent fairly large retrospective/prospective registry-based international study showed that PT-VWD is very rare, likely to be misdiagnosed as type 2B VWD or idiopathic thrombocytopenic purpura, and represents 15% of type 2B VWD diagnoses.
KEYWORDS
Glycoprotein 1bα - type 2B VWD - registry - RIPA - PT-VWD mouse - platelet concentrate
REFERENCES
1
Weiss H J, Meyer D, Rabinowitz R et al.
Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers.
N Engl J Med.
1982;
306
(6)
326-333
2
Othman M.
Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes.
Semin Thromb Hemost.
2007;
33
(8)
780-786
3
Miller J L, Castella A.
Platelet-type von Willebrand's disease: characterization of a new bleeding disorder.
Blood.
1982;
60
(3)
790-794
4 Registry PT-VWD. Available at: http://http//www.pt-vwd.org Accessed February 9, 2011
5
Lopez J A, Chung D W, Fujikawa K, Hagen F S, Papayannopoulou T, Roth G J.
Cloning of the alpha chain of human platelet glycoprotein Ib: a transmembrane protein with homology to leucine-rich alpha 2-glycoprotein.
Proc Natl Acad Sci U S A.
1987;
84
(16)
5615-5619
6
Ware J, Russell S, Ruggeri Z M.
Cloning of the murine platelet glycoprotein Ibalpha gene highlighting species-specific platelet adhesion.
Blood Cells Mol Dis.
1997;
23
(2)
292-301
7
Miller J L, Cunningham D, Lyle V A, Finch C N.
Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease.
Proc Natl Acad Sci U S A.
1991;
88
(11)
4761-4765
8
Russell S D, Roth G J.
Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor.
Blood.
1993;
81
(7)
1787-1791
9
Takahashi H, Murata M, Moriki T et al.
Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease.
Blood.
1995;
85
(3)
727-733
10
Kunishima S, Heaton D C, Naoe T et al.
De novo mutation of the platelet glycoprotein Ib alpha gene in a patient with pseudo-von Willebrand disease.
Blood Coagul Fibrinolysis.
1997;
8
(5)
311-315
11
Huizinga E G, Tsuji S, Romijn R A et al.
Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain.
Science.
2002;
297
(5584)
1176-1179
12
Murata M, Russell S R, Ruggeri Z M, Ware J.
Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment.
J Clin Invest.
1993;
91
(5)
2133-2137
13
Moriki T, Murata M, Kitaguchi T et al.
Expression and functional characterization of an abnormal platelet membrane glycoprotein Ib alpha (Met239—> Val) reported in patients with platelet-type von Willebrand disease.
Blood.
1997;
90
(2)
698-705
14
Matsubara Y, Murata M, Sugita K, Ikeda Y.
Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease.
J Thromb Haemost.
2003;
1
(10)
2198-2205
15
Nurden P, Lanza F, Bonnafous-Faurie C, Nurden A.
A second report of platelet-type von Willebrand disease with a Gly233Ser mutation in the GPIBA gene.
Thromb Haemost.
2007;
97
(2)
319-321
16
Othman M, Notley C, Lavender F L et al.
Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease.
Blood.
2005;
105
(11)
4330-4336
17
Uff S, Clemetson J M, Harrison T, Clemetson K J, Emsley J.
Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation.
J Biol Chem.
2002;
277
(38)
35657-35663
18
Dumas J J, Kumar R, McDonagh T et al.
Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations.
J Biol Chem.
2004;
279
(22)
23327-23334
19
Othman M.
Differential identification of PT-VWD from type 2B VWD and GP1BA nomenclature issues.
Br J Haematol.
2008;
142
(2)
312-314
author reply 314-315
20
Miller J L.
Platelet-type von Willebrand disease.
Thromb Haemost.
1996;
75
(6)
865-869
21
Federici A B, Mannucci P M, Castaman G et al.
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.
Blood.
2009;
113
(3)
526-534
22
Nurden A T.
Qualitative disorders of platelets and megakaryocytes.
J Thromb Haemost.
2005;
3
(8)
1773-1782
23
Favaloro E J.
2B or not 2B? Differential identification of type 2B, versus pseudo-von Willebrand disease.
Br J Haematol.
2006;
135
(1)
141-142
author reply 143
24
Favaloro E J.
Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?.
Semin Thromb Hemost.
2008;
34
(1)
113-127
25
Favaloro E J, Patterson D, Denholm A et al.
Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis.
Br J Haematol.
2007;
139
(4)
623-626
26
Whalley I N, Perry D J.
2B or not 2B? Differential identification of type 2B, versus pseudo von Willebrand disease.
Br J Haematol.
2007;
136
(2)
345
author reply 345-346
27
Othman M, Lillicrap D.
Distinguishing between non-identical twins: platelet type and type 2B von Willebrand disease.
Br J Haematol.
2007;
138
(5)
665-666
28
Othman M, Hamilton A.
Platelet-type von Willebrand disease: results of a worldwide survey from the Canadian PT-VWD project.
Acta Haematol.
2010;
123
(2)
126-128
29
Enayat M S, Guilliatt A M, Lester W, Wilde J T, Williams M D, Hill F G.
Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance.
Br J Haematol.
2006;
133
(6)
664-666
30
Giannini S, Cecchetti L, Mezzasoma A M, Gresele P.
Diagnosis of platelet-type von Willebrand disease by flow cytometry.
Haematologica.
2010;
95
(6)
1021-1024
31
Franchini M, Montagnana M, Lippi G.
Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease.
Int J Lab Hematol.
2008;
30
(2)
91-94
32
Guerrero J A, Kyei M, Russell S et al.
Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation.
Blood.
2009;
114
(27)
5541-5546
33
Suva L J, Hartman E, Dilley J D et al.
Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease.
Am J Pathol.
2008;
172
(2)
430-439
34
Rodeghiero F, Castaman G, Dini E.
Epidemiological investigation of the prevalence of von Willebrand's disease.
Blood.
1987;
69
(2)
454-459
35
Favaloro E.
von Willebrand disease: local diagnosis and management of a global issue.
Semin Thromb Hemost.
2011;
37
(5)
440-455
36
Hamilton A, Ozelo M, Leggo J et al.
Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study.
Thromb Haemost.
2011;
105
(3)
501-508
Maha OthmanM.D. Ph.D.
Department of Anatomy and Cell Biology, Queen's University, Boterell Hall
Room 915, Kingston, Ontario K7L 3N6, Canada
eMail: Othman@queensu.ca